During his fourteen year career with Becton, Dickinson and Co. ("BD") (NYSE: BDX), one of the world's leading suppliers of medical, diagnostic and life science research products, Bill held a number of senior leadership positions, and until the end of 2012, was BD's Senior Vice President, Corporate Strategy and Development, being responsible for BD's worldwide mergers and acquisitions and corporate strategies.

Previously, he was Worldwide President of BD Biosciences, a business segment with turnover of over US$1.0 billion that was comprised of Cell Analysis, Discovery Labware, and Advanced Bioprocessing, including the provision of flow cytometryinstruments and their associated reagents for CD4 testing used in a wide range of laboratory settings. Bill was also responsible for creating BD Ventures L.L.C., the venture capital arm of BD. Prior to working for BD, Bill held senior business development positions with Pfizer Inc. and Johnson and Johnson. He recently joined Linden Capital Partners, a leading US-based healthcare private equity firm, as Operating Partner responsible for life sciences and diagnostics.

Commenting on Bill's appointment, David Evans, Chairman of Omega said: "We are delighted to have attracted someone of Bill's calibre to the Omega team. His all-round experience in corporate business development, life sciences and in vitro diagnostics business leadership and his expansive knowledge of emerging and developing world markets where HIVmonitoring and CD4 testing are major areas of clinical need will be invaluable to us."

Bill Rhodes said: "I am pleased to have been asked to join the Board of Omega. With opportunities to expand their current portfolio of products globally, and the on-going development of their novel test platform for point of care CD4 testing, now is a very exciting time for the Company, and I look forward to working with the Omega team."